title: Macroprolactinemia in a patient with invasive macroprolactinoma: a case report and minireview.
abstract: Background. Macroprolactin, the high-molecular prolactin isoform, is considered to be an inactive in vivo product with extrapituitary origin. Patients with macroprolactinemia are usually asymptomatic, with negative pituitary imaging. Based on these data, most authors do not recommend treatment and long-term followup in subjects with macroprolactinemia. However, there is evidence for overlapping clinical features among subjects with hyperprolactinemia due to monomeric or "big big" PRL isoform. Case Presentation. We present a 35-year-old female patient with secondary amenorrhea, mild obesity, hirsutism, headache and blurred vision. Hormonal evaluation revealed an extreme hyperprolactinemia (PRL = 10 610 mIU/L) almost exclusively due to macroprolactin isoform (MPRL = 10 107 mIU/L; recovery after PEG precipitation 4.7%) and hypogonadotropic hypogonadism. An invasive pituitary macroadenoma was visualized on MRI, and cabergoline therapy was initiated. Disappearance of clinical signs and symptoms, normalization of gonadotropin levels, and restoration of regular ovulatory menstrual cycles after 1 year of treatment are arguments in favor of preserved-macroprolactin bioactivity in this case. The significant decrease in MPRL levels and tumor volume in response to dopamine agonist therapy is suggestive for the tumoral origin of this isoform. Conclusions. Although macroprolactinemia is considered to be a benign condition, pituitary imaging, dopamine agonist treatment, and prolonged followup should be recommended in some particular cases.
authors: USHATE "Acad. Ivan Pentchev", Clinical Centre of Endocrinology and Gerontology, Medical University-Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria.
authors: Atanaska
authors: A
authors: Elenkova
authors: Zdravka
authors: Z
authors: Abadzhieva
authors: Nikolai
authors: N
authors: Genov
authors: Vladimir
authors: V
authors: Vasilev
authors: Georgi
authors: G
authors: Kirilov
authors: Sabina
authors: S
authors: Zacharieva
references: Endocrine. 2012 Apr;41(2):327-33
references: 22187359
references: Endocr Pract. 2006 May-Jun;12(3):275-80
references: 16772199
references: Eur J Endocrinol. 2003 Sep;149(3):201-7
references: 12943522
references: Clin Chim Acta. 2010 Feb;411(3-4):155-60
references: 19895797
references: J Clin Endocrinol Metab. 1989 Sep;69(3):585-92
references: 2503534
references: Endocrinol Jpn. 1987 Jun;34(3):325-34
references: 3115763
references: J Clin Endocrinol Metab. 2005 May;90(5):3036-44
references: 15687336
references: Endocrine. 2012 Feb;41(1):138-43
references: 21959531
references: Clin Chem Lab Med. 2001 Dec;39(12):1244-8
references: 11798085
references: Clin Endocrinol (Oxf). 1992 Oct;37(4):365-72
references: 1483294
references: Minerva Endocrinol. 2007 Jun;32(2):79-86
references: 17557033
references: Clin Endocrinol (Oxf). 1999 Jul;51(1):119-26
references: 10468974
references: Orv Hetil. 2010 Jun 27;151(26):1072-5
references: 20558354
references: Hum Reprod. 2003 Apr;18(4):853-7
references: 12660284
references: J Clin Endocrinol Metab. 2005 Jul;90(7):3927-32
references: 15811931
references: Endocr Rev. 1995 Jun;16(3):354-69
references: 7671851
references: Clin Endocrinol (Oxf). 2003 Sep;59(3):339-46
references: 12919157
references: J Clin Endocrinol Metab. 2001 Jun;86(6):2743-6
references: 11397880
references: Horm Metab Res. 1989 Feb;21(2):84-8
references: 2722134
references: Kaohsiung J Med Sci. 2011 May;27(5):173-6
references: 21527183
references: J Clin Endocrinol Metab. 1985 Aug;61(2):258-64
references: 4008606
references: Eur J Clin Invest. 2007 Jul;37(7):552-7
references: 17576206
references: Acta Clin Belg. 2005 Sep-Oct;60(4):190-7
references: 16279400
references: Clin Endocrinol (Oxf). 2010 Dec;73(6):792-7
references: 20874771
references: Endocrine. 2010 Apr;37(2):294-300
references: 20960266
references: Acta Med Port. 2011 Dec;24 Suppl 4:929-38
references: 22863502
references: J Clin Endocrinol Metab. 1974 Nov;39(5):928-35
references: 4213557